What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 7.8% in the afternoon session after investment firm Piper Sand...
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 30.2% in the afternoon session after the company reported better-than-expected fourth-quarter financial results.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15% year on year to $290.4 million. On the other hand, the company’s full-year revenue guidance of $543 million at the midpoint came in 50.7% below analysts’ estimates. Its GAAP loss of $0.01 per share was 84.4% above analysts’ consensus estimates.
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings per share (EPS) of $1.55, significantly outstripping Wall Street’s consensus estimate of $1.46. Revenue for the quarter reached $783.8 million,
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Over the past six months, Tandem Diabetes has been a great trade, beating the S&P 500 by 9.6%. Its stock price has climbed to $19.83, representing a healthy 17.8% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Today’s Date: January 9, 2026 Introduction In the rapidly evolving landscape of medical technology, few companies have managed to fundamentally reshape a multi-decade standard of care as successfully as Insulet Corporation (NASDAQ: PODD). Historically, insulin delivery was synonymous with either multiple daily injections (MDI) or cumbersome, tubed mechanical pumps. Insulet disrupted this paradigm with the [...]
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare technology stocks fared in Q3, starting with Tandem Diabetes (NASDAQ:TNDM).
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
